Base de dados : LILACS
Pesquisa : D03.383.742.680.245 [Categoria DeCS]
Referências encontradas : 3 [refinar]
Mostrando: 1 .. 3   no formato [Detalhado]

página 1 de 1

  1 / 3 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-984016
Autor: Zhang, Jingmin; Wang, Yafeng; Peng, Youmei; Qin, Chongzhen; Liu, Yixian; Li, Jingjing; Jiang, Jinhua; Zhou, Yubing; Chang, Junbiao; Wang, Qingduan.
Título: Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model
Fonte: Braz. j. infect. dis;22(6):477-486, Nov.-Dec. 2018. tab, graf.
Idioma: en.
Projeto: This work was supported by grants from the Natural Science Foundation of China; . Young Innovation Foundation of The First Affiliated Hospital of Zhengzhou University of China.
Resumo: ABSTRACT Antiviral drug resistance is the most important factor contributing to treatment failure using nucleos(t)ide analogs such as lamivudine for chronic infection with hepatitis B virus (HBV). Development of a system supporting efficient replication of clinically resistant HBV strains is imperative, and new antiviral drugs are needed urgently to prevent selection of drug-resistant HBV mutants. A novel fluorinated cytidine analog, NCC (N-cyclopropyl-4′-azido-2′-deoxy-2′-fluoro-β-d-cytidine), was recently shown to strongly inhibit human HBV in vitro and in vivo. This study was designed to evaluate the antiviral activity of NCC against lamivudine-resistant HBV. We generated a stable cell line encoding the major pattern of lamivudine-resistant mutations rtL180M/M204V and designated it "HepG2.RL1". Immuno-transmission electron microscopic examination and enzyme-linked immunosorbent assay were used to detect secretion of HBV-specific particles and antigens. Quantification of extracellular DNA and intracellular DNA of HepG2.RL1 cells by quantitative real-time polymerase chain reaction revealed >625-fold and >5556-fold increases in the 50% inhibitory concentration of lamivudine, respectively, compared with that for the wild-type virus. The results showed that NCC inhibited DNA replication and HBeAg production in wild-type or lamivudine-resistant HBV in a dose-dependent manner. In conclusion, screening for antiviral compounds active against lamivudine-resistant HBV can be carried out with relative ease using hepG2.RL1 cells. NCC is a potential antiviral agent against wild-type HBV and clinical lamivudine-resistant HBV and deserves evaluation for the treatment of HBV infection.
Descritores: Antivirais/farmacologia
Replicação Viral/efeitos dos fármacos
Vírus da Hepatite B/efeitos dos fármacos
Lamivudina/farmacologia
Citidina/análogos & derivados
-DNA Viral/química
Testes de Sensibilidade Microbiana
Linhagem Celular
Vírus da Hepatite B/isolamento & purificação
Vírus da Hepatite B/fisiologia
Hepatócitos/virologia
Farmacorresistência Viral/efeitos dos fármacos
Mutação
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  2 / 3 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-536530
Autor: Goldberg, Henrique; Scussel Júnior, Ari Boulanger; Cohen, José Carlos; Rzetelna, Helio; Mezitis, Spyros G. E; Nunes, Fabio Pereira; Ozeri, David; Daher, João Paulo Lima; Nunes, Carlos Pereira; Oliveira, Lisa; Geller, Mauro.
Título: Neural compression-induced neuralgias: clinical evaluation of the effect of nucleotides associated with vitamin B12
Fonte: RBM rev. bras. med;66(11), nov. 2009.
Idioma: pt.
Resumo: The use of a combination of uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxocobalamin was evaluated in a double-blind, randomized study in the treatment of neuralgia due to degenerative orthopedic alterations with neural compression. Following informed consent, 80 patients were randomized to a 30 day treatment period. The subjects received a thrice-daily oral treatment regimen of either the combination treatment (Group A: total daily dose of 9mg UTP, 15mg CMP, 6 mg hydroxocobalamin) or vitamin B12 alone (Group B: total daily dose of 6 mg hydroxocobalamin). Efficacy measures evaluated global patient condition from the perspective of the subject and the investigating physician pain ? measured by a visual-analog scale and functionality, using a patient-response questionnaire. The safety evaluation took into account physical evaluations and laboratory tests performed at each visit to the study center as well as the incidence and severity of adverse events. At the end of the 30-day treatment period, there were reductions in the pain scale scores in both groups, however there was a significantly larger reduction in the scores of the Group A patients. The Patient Global Evaluation scores improved in both groups but showed greater improvement in Group A, while the Physician Global Evaluation improved significantly only in Group A. A similar finding was observed in the scores of the Patient Functionality Questionnaire. Based on the findings of this clinical trial, we conclude that the combination of UTP, CMP, and vitamin B12 has a positive effect on pain and functionality improvement in the treatment of degenerative orthopedic alterations with neural compression, in the study population evaluated.
Descritores: Citidina/uso terapêutico
Uridina/uso terapêutico
/uso terapêutico
VITAMINA B ABETALIPOPROTEINEMIA/uso terapêutico
-Neuralgia/tratamento farmacológico
Limites: Adulto
Pessoa de Meia-Idade
Tipo de Publ: Estudo Comparativo
Responsável: BR12.1 - Biblioteca Setorial da Ciências da Saúde


  3 / 3 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Id: lil-133121
Autor: Guevara Iribarren, José; Isausti, Carmen Luisa de; Lamillo, Inaty; Lara, Dalia de; Guevara Palma, José.
Título: Leucemía mieloide aguda en niños del Hospital Universitario de Caracas (Período 1979-1989) / Acute myeloid leukemia in children at the University Hospital of Caracas (period 1979-1989)
Fonte: Arch. venez. pueric. pediatr;55(2):48-54, abr.-jun. 1992. tab.
Idioma: es.
Resumo: En el Hospital Universitario de Caracas 52 nuevos casos de Laucemia Mieloblástica aguda (LMA) fueron tratados en dos series consecutivas entre 1979-1989. Concomitantemente se intentó correlacionar los hallazgos clínicos y de laboratorio al ingreso, y la respuesta al tratamiento, con los subtipos morfológicos (FAB) de LMA. Serie I (1979-1985): comprendió 37 niños que recibieron principalmente la terapia de inducción con Citosina Arabinosa 100 mg/m2/día, en una infusión continua por 7 días, además de Daunomicina 45 mg/m2/día, en los 3 primeros días del tratamiento. La serie II incluyó solo 15 pacientes tratados en igual forma, excepto por la Citosina Arabinosa que se administró durante 10 días. Los pacientes que alcanzaron remisión en ambas series recibieron luego 5 ciclos con el esquema de COAP como terapia de consolidación. Posteriormente, fueron a un tratamiento de mantenimiento semanal con 6-Thioguanima por 4 días más Citosina Arabinosa el 5to. día durante 24 meses en remisión contínua. el tratamineto de inducción se realizó en 44 niños, dado que 7 murieron durante la fase de inducción en aplasia y otro caso se descartó por Síndrome de Down. La remisión completa fue de 64 por ciento (21/33) en la Serie I y de 36 por ciento (4/11) en la Serie II; observandose en ambas series un 42 por ciento de LMA con un componente monocítico, la mayoría del tipo M4 y 80 por ciento (20/25) de los casos que alcanzaron remisión, presentaban diferenciación mieloide FAB M1-M4. La duración de la remisión fué corta, lo que sugiere fallas en el tratamiento citotócico recayendo el 60 por ciento en los primeros 6 meses. La sobrevida libre de enfermedad fue menor de 20 por ciento al año y de sólo 6 por ciento a los 30 meses, sin diferencias estadísticas significativas en las 2 Series. Se estima que la problemática asistencial crónica de nuestro hospital pudo haber influido en la alta tasa de mortalidad temprana. Esta es la primera casuística de niños con LMA reportada en Venezuela
Descritores: Citidina/uso terapêutico
Citosina/administração & dosagem
Daunorrubicina/administração & dosagem
Daunorrubicina/uso terapêutico
Leucemia Mieloide Aguda/tratamento farmacológico
Limites: Criança
Humanos
Tipo de Publ: Estudo Comparativo
Responsável: VE1.1 - Biblioteca Humberto Garcia Arocha



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde